Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression in CD3/CD28 stimulated CD8 vs CD8 with various dosage of Cholesterol treatment

ABSTRACT: Gene expression in CD3/CD28 stimulated CD8 vs CD8 with various dosage of Cholesterol treatment

PROVIDER: PRJNA449448 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Gene expression in CD3/CD28 stimulated CD8 vs CD8 with various dosage of Cholesterol treatment

Project description:gene expression in in vitro diffrerentiated CD8 (CD3/CD28 stimulation ) T cells and CD8 T cells treated with Cholesterol

2020-04-14 | GSE112901 | GEO

RNA-seq profiling of in vitro FRC-conditioned, IL6-conditioned or control (anti-CD3/CD28)-stimulated CD8+ T cells

Project description:To broadly assess which pathways FRCs regulate in CD8+ T cells, we sorted CD8+ T cells for RNA-seq following activation in whole splenocyte mixtures via soluble anti-CD3/CD28 for 48 hours (Stim), activated with anti-CD3/CD28 in the presence of Nos2–/– FRCs (FRC) or activated with anti-CD3/CD28 plus 100 ng/ml recombinant IL-6 (IL-6). Here we demonstrate that FRC-derived signals, including IL-6, act in concert with TCR signaling and co-stimulation to promote the expression of MYC and HIF-1-dependent glycolytic genes and vital pro-survival genes (encoding BCL-2 family members, inhibitors of apoptosis [IAPs] members and Cflar) in activated CD8+ T cells.

2019-10-14 | GSE136898 | GEO

Genome wide expression profiles (RNAseq) of human CD8+ T cells in resting, activated (CD3+CD28) and PD-1-stimulated cells (CD3+CD28+PD-L1-Fc) at diferent time points

Project description:Background: Binding of the programmed death-1 (PD-1) receptor to its ligands (PD-L1/2) transduces inhibitory signals that promote exhaustion of activated T cells. Blockade of the PD 1 pathway is widely used for cancer treatment, yet the inhibitory signals transduced by PD-1 in T cells remain elusive. Methods: Expression profiles of human CD8+ T cells in resting, activated (CD3+CD28) and PD-1-stimulated cells (CD3+CD28+PD-L1-Fc) conditions were evaluated by RNA-seq. Bioinformatic analyses were used to identify signaling pathways differentially regulated in PD 1-stimulated cells.

2019-05-29 | GSE122149 | GEO

ATAC-seq profiling of in vitro FRC-conditioned, IL6-conditioned or control (anti-CD3/CD28)-stimulated CD8+ T cells

Project description:To broadly assess which pathways FRCs regulate in CD8+ T cells, we sorted CD8+ T cells for ATAC-seq following activation in whole splenocyte mixtures via soluble anti-CD3/CD28 (0.25μg/ml) for 48 hours (Stim), activated with anti-CD3/CD28 in the presence of Nos2–/– FRCs (FRC) or activated with anti-CD3/CD28 plus 100 ng/ml recombinant IL-6 (IL-6). Here we demonstrate that FRC-derived signals, including IL-6, act in concert with TCR signaling and co-stimulation to remodel chromatin and render essential transcription factor binding motifs accessible in activated CD8+ T cells. Signals from FRCs led to increased binding regions for MYC, HIF-1α and HIF-1β, which are known to promote metabolic pathways following T cell activation. Additionally, FRC-derived signals promoted activity of transcription factors that regulate survival and memory programs in T lymphocytes such as BATF and BACH2.

2019-10-14 | GSE136903 | GEO

CD3/CD28 and IL-2 stimulated mouse CD8 T cells with or without anti-CD132 blocking antibody

Project description:Mouse CD8 T cells were isolated from total splenocytes from C57BL/6 mice by MACS separation. Cells were incubated for 48 h with CD3/CD28 DynaBeads and 50 ng/ml IL-2 for 48 h with or without 100 nm anti-CD132 blocking antibody. Cells were collected and RNA was isolated.

2015-03-23 | E-MTAB-2960 | biostudies-arrayexpress

CD3/CD28 Stimulated versus unstimulated Double-negative T Cells From Sooty Mangabeys

2012-12-31 | GSE40781 | GEO

CD3/CD28 signaling, Jurkat E6.1, time course 27 mins

Project description:Fe-IMAC phosphoproteomics using TMT 11plex for quant, of Jurkat T cells stimulated with CD3 and CD28 agonist antibodies for 0, 3, 9, or 27 minutes.

| MSV000092965 | MassIVE

CD3/CD28 Stimulated versus unstimulated Double-negative T Cells From Sooty Mangabeys

Project description:Transcriptional profiling of Double Negative (CD4-/CD8-) T-cells isolated from SIV infected Sooty Mangebys. DN T-cells were stimulated through the T-Cell receptor using anti CD3/CD28 antibodies for 4 hours and compared to unstimulated DN T-cells. Two condition experiment, Stimulated vs Unstimulated. 4 animals tested, each with Stim vs Unstim, a dye flip of Stim vs Unstim, Stim vs Stim and Unstim vs Unstim.

2012-12-31 | E-GEOD-40781 | biostudies-arrayexpress

Transcription profiling of human CD8 T cells activated with CD3 or CD3-CD28 prior to retroviral transduction and different selection procedures (G418 or NGFR-MACS)n

Project description:effect of different T cell activations (CD3 and CD3-CD28) prior retroviral transduction and different selection procedures (G418 or NGFR-MACS)

2007-06-01 | E-MEXP-973 | biostudies-arrayexpress

RNA sequencing analysis of anti-CD3/CD28 stimulated wild type-OT1 (WT) and Lrch1-/- -OT1 (KO) CD8+ T cells

Project description:We report the differential gene expression between anti-CD3/CD28 stimulated WT and LRCH1-deficient CD8+ T cells. Improving cytotoxicity, proliferation and infiltration ability of CD8+ T cells is critical in T cell immunotherapies against tumors. This study has identified LRCH1 as a negative regulator of LAT-mediated TCR signal transduction, as LRCH1 inhibits LAT signalosome formation and facilitates the endocytosis of LAT on the plasma membrane. LRCH1-deficient CD8+ T cells are more proliferative and effective at pathogen control and tumor elimination. Importantly, CRISPR/Cas9-mediated knockout of LRCH1 in human T cells also increases IFN-γ production, cell proliferation and migration ability in vitro. These data suggest LRCH1 as a potential target to improve CD8+ T cell responses against tumor and pathogens.

2020-07-29 | GSE150634 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data